drugset / Trial / NCT00994916

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

NCT00994916

Expanded access No longer available David Lacomis, MD Jacobus Pharmaceutical · collab

Summary

The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amifampridine Small molecule 80 mg